Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid

Therapeutic Drug Monitoring

Volumn 31, Issue 5, 2009, Pages 542-548

  Yang, Jae Wook ^a,b   Lee, Puay Hoon ^c   Hutchinson, Ian V ^a,d   Pravica, Vera ^a,d   Shah, Tariq ^a,b,d,e   Min, David I ^a,b,e  

^a National Institute of Transplantation Los Angeles   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e ST VINCENT MEDICAL CENTER   (United States)

Author keywords

Gastrointestinal Symptom Rating Scale; Genetic polymorphisms; Mycophenolic acid

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; GLUCURONOSYLTRANSFERASE 2B7; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GRAFT REJECTION; HETEROZYGOTE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; THALASSEMIA MAJOR;

CALCINEURIN; GLUCURONOSYLTRANSFERASE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES;

EID: 70349658283     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181b1dd5e     Document Type: Article

References (28)

1. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation. 2006; 82:102-107.
2. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 2003;14:2381-2386.
3. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation. 2006;81:1290-1297.
4. Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patientreported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation. 2007;84:1443-1451.
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
6. Hesselink DA, Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther. 2005;78:317-321.
7. Shipkova M, Amstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites; toxicological and analytical implications. Ther Drug Monit. 2003;25:1-16.
8. Badelli S, Merlini S, Perico N, et al. C-440/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007;8:1127-1141.
9. Djebli N, Picard N, Rerolle JP, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genom. 2007;17:321-330.
10. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139-146.
11. Randominska-Pandya A, Little JM, Czernik PJ. Human UDP-glucuronosyl- transferase 2B7. Curr Drug Metab. 2001;2:283-298.
12. Naesens M, Kuypers DRJ, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82:1074-1084.
13. Saitoh H, Kobayashi M, Oda M, et al. Characterisation of intestinal absorption and enterohepatic circulation of mycohenolic acid and its 7-o-glucuronide in rats. Drug Metab Pharmacokinet. 2006;21:406-413.
14. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation. 1998;66:1115-1116.
15. Shipkova M, Beck H, Voland A, et al. Identification of protein targets for mycophenolic acid acyl gluconide in rat liver and colon tissue. Proteomics. 2004;4:2728-2738.
16. Levesque E, Delage R, Benoit-Biancamano M-O, et al. The Impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81:392-400.
17. Bernard O, Tojcic J, Jorunault K, et al. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Disposit. 2006;34:1539-1545.
18. Daly AK, Aithal GP, Leathart JBS, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132:272-281.
19. Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007;81:42-49.
20. Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001;11:175-184.
21. Itoda M, Saito Y, Soyama A, et al. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. Drug Metab Dispos. 2002;30:363-364.
22. Kleinman L, Kilburg A, Machnicki G, et al. Using GI-specific patient outcome measures in renal transplant patients: Validation of the GSRS and GIQLI. Qual Life Res. 2006;15:1223-1232.
23. Lamas K, Lindholm L, Stenlund H, et al. Effects of abdominal massage in management of constipation- A randomized controlled trial. Internat J Nurs Stud. 2009;46:759-767.
24. Machnicki G, Pefaur J, Gaite L, et al. Gastrointestinal (GI)-specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American Cohort. Health Qual Life Outcomes. 2008;6:53-62.
25. Heller T, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant. 2007;7:1822-1831.
26. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237-243.
27. Meier-Kriesche HU, Davies NM, Grinyo J, et al. Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. Am J Transplant. 2005;5:1164-1166.
28. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. New Eng J Med. 2003;348:538-549.